Prevision Medicine offers an ex vivo drug sensitivity platform that tests a patient’s live cancer and healthy cells against a panel of over 100 drugs and combinations. The resulting clinical report, delivered within three days, ranks treatments by their ability to selectively kill cancer cells while sparing normal tissue. This functional profiling enables oncologists to make data-driven treatment decisions, improving outcomes for patients with limited therapeutic options.
Funding
Funding not disclosed
Founders
Product
Problem
Current medical treatments often follow a one-size-fits-all approach, neglecting individual biological differences that can significantly impact treatment effectiveness and patient outcomes. This lack of personalization can lead to suboptimal treatment selection and potentially adverse effects.
Solution
Prevision Medicine aims to optimize treatment strategies by leveraging functional data to create personalized treatment plans tailored to each individual's unique biological characteristics. By analyzing patient-specific data, the company seeks to understand how a patient's individual biology will respond to different treatments. This approach allows for the selection of treatments that are most likely to be effective for a specific patient, ultimately improving patient outcomes and reducing the risk of ineffective or harmful treatments.
Target Audience
The primary target audience includes healthcare providers, hospitals, and research institutions seeking to improve patient outcomes through personalized medicine.
Features
- Patient-specific data analysis to identify unique biological characteristics.
- Personalized treatment plan generation based on individual patient profiles.
- Optimization of treatment selection for improved effectiveness.